Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial - Scorecard - MDSpire
Advertisement
Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial
Clinical Scorecard: Evaluation of HS-20137 in Chinese Patients with Moderate-to-Severe Psoriasis: Results from a Phase 2, Randomized, Double-Blind Trial
At a Glance
Category
Detail
Condition
Moderate-to-severe plaque psoriasis
Key Mechanisms
HS-20137 is a humanized IgG1λ monoclonal antibody targeting the p19 subunit of IL-23, inhibiting IL-23 mediated inflammatory pathways
Target Population
Chinese patients aged 18–75 years with moderate-to-severe plaque psoriasis (IGA ≥3, PASI ≥12, BSA ≥10%)
Care Setting
Multicenter clinical trial and potential outpatient dermatology care
Key Highlights
HS-20137 significantly improved psoriatic lesions and quality of life over 52 weeks with a favorable safety profile.
The study demonstrated sustained efficacy with dosing every 8 or 12 weeks after initial doses.
Findings support HS-20137 as a competitive treatment option among IL-23 inhibitors for moderate-to-severe psoriasis.
Guideline-Based Recommendations
Diagnosis
Diagnosis based on clinical assessment including Investigator Global Assessment (IGA), Psoriasis Area Severity Index (PASI), and body surface area (BSA) involvement.
Management
Use of biologic agents targeting IL-23p19 such as HS-20137 for moderate-to-severe plaque psoriasis.
Dosing regimen includes initial doses at weeks 0 and 4, followed by maintenance dosing every 8 or 12 weeks.
Consider switching placebo patients to active treatment after initial period for ethical and efficacy reasons.
Monitoring & Follow-up
Regular assessment of PASI scores (including PASI 75, 90, and 100) and IGA scores to evaluate treatment response.
Monitoring Dermatology Life Quality Index (DLQI) to assess patient quality of life improvements.
Safety monitoring including adverse events, serious adverse events, and laboratory evaluations throughout treatment and follow-up.
Risks
Potential adverse events related to immunomodulation; no serious adverse events reported in the study.
Exclusion of patients with active or untreated latent tuberculosis or chronic infections to mitigate infection risks.
Patient & Prescribing Data
Chinese adults with moderate-to-severe plaque psoriasis without prior IL-12/IL-23 or IL-23 targeted therapy.
HS-20137 demonstrated strong binding affinity to IL-23p19 with sustained efficacy and safety up to 52 weeks, supporting its use as a long-term treatment option.
Clinical Best Practices
Screen patients thoroughly to exclude non-plaque psoriasis and active infections before initiating HS-20137.
Adhere to dosing schedules with initial loading doses followed by maintenance injections every 8 or 12 weeks.
Monitor efficacy using standardized PASI and IGA scoring systems and assess quality of life improvements.
Conduct ongoing safety surveillance including adverse event reporting and laboratory monitoring.
Educate patients on the chronic nature of psoriasis and the importance of adherence to long-term biologic therapy.
